Radioactive 'Smart Bomb' targets Hard-to-Treat breast cancer

NCT ID NCT04529044

Recruiting now Disease control Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a radioactive drug called 177Lu-DOTATATE in 10 people with stage IV or recurrent breast cancer. The drug seeks out cancer cells that have a specific receptor (SSTR2) and delivers radiation to kill them. The goal is to see if it can shrink tumors and reduce cancer stem cells in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-DOTATATE (a radioactive drug that targets tumor cells with SSTR2)
What this could lead to: If it works, this could offer a new treatment option for people with advanced breast cancer that has a specific marker (SSTR2).
What could go wrong: This is a very small, early-phase pilot study with only 10 participants, so results may not apply to everyone. The treatment involves radiation, which can cause side effects, and it may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 METASTATIC BREAST CARCINOMA RECURRENT BREAST CARCINOMA

Radioactive 'Smart Bomb' targets Hard-to-Treat breast cancer

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions